UniHealth

Date: November 14, 2026

To
The Manager,
Listing Department,
National Stock Exchange of India Ltd.,
Exchange Plaza, Plot No. C-1, Block G,
Bandra Kurla Complex, Bandra (E), Mumbai – 400051.

NSE SYMBOL: UNIHEALTH

Dear Sir/ Madam,

Sub: Outcome of the Board Meeting - November 14, 2026

Ref: Intimation under Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations").

Pursuant to Regulation 30 and 33 of SEBI Listing Regulations, this is to inform that the Board of Directors at its meeting held on Saturday, November 14, 2026, inter-alia, transacted the following business:

1. Considered and approved the Unaudited Standalone and Consolidated Financial Results for the half year ended September 30, 2026, together with the Limited Review Report of the Auditor's thereon, Statement of Assets and Liabilities and Cashflow statement as at September 30, 2026 which are enclosed herewith.

Further, please find enclosed the following:

1. Statement of Deviation or Variation as required under Regulation 32(1) of the SEBI Listing Regulations.

2. Certificate indicating utilisation of issue proceeds pursuant to NSE circular No: NSE/CML/2024/23 dated September 05, 2024.

The trading window for dealing in securities of the Company shall open on Tuesday, November 17, 2026, being 48 hours after declaration of Financial Results by the Company for the half year ended September 30, 2026. The Meeting commenced at 15.30 P.M. and concluded at 16:05 P.M.

Kindly take the above on your records.

Thanking you.

UniHealth

Yours faithfully,

For Unihealth Hospitals Limited
(Formerly Unihealth Consultancy Limited)

DESHNA JAIN
Digitally signed by DESHNA JAIN
Date: 2026.11.14 18:07:32 +05'30'

Deshna Jain
Company Secretary & Compliance Officer
Encl.: As above

UNIHEALTH HOSPITALS LIMITED MUMBAI

G. P. KAPADIA & CO.
Chartered Accountants
4th Floor, Hamam House, Ambalal Doshi Marg, Fort, Mumbai - 400 001
+ 91 22 2265 4239 / 4313 info.ho@gpkapadia.com www.gpkapadia.com

Independent Auditors' Review Report for the half year ended 30th September, 2026 on Unaudited Standalone Financial Results of Unihealth Hospitals Limited (Formerly Known as Unihealth Consultancy Limited) under regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended.

To,
Board of Directors,
Unihealth Hospitals Limited
(Formerly Known as Unihealth Consultancy Limited)

1. We have reviewed the accompanying statement of unaudited standalone financial results of **Unihealth Hospitals Limited** (herein after referred as 'the Company') *(Formerly Known as Unihealth Consultancy Limited)* for the Half Year ended 30th September 2026 (the 'Statement'), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and
Disclosure Requirements) Regulations, 2015, as amended (the 'Listing Regulations')

2. This statement, which is the responsibility of The Company's Management and approved by the company's board of directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under section 133 of The Companies Act 2013, as amended, read with relevant rules issued thereunder and accounting principles generally accepted in India and in compliance with Regulation 33 of Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted and procedures performed as stated in paragraph 3 above, as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared with the recognition and measurement principles laid down in accordance with applicable Indian Accounting Standards ("Ind AS") prescribed under section 133 of The Companies Act 2013 as amended, read with relevant Rules issued thereunder and other recognized accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For G.P Kapadia & Co.
(Chartered Accountants)
FRN No.: 104768W

Atul Babubhai Desai

Digitally signed by Atul Babubhai Desai
Date: 2026.11.14 17:16:47 +05'30'

Atul Desai
(Partner)
Membership No. 030850
Place: Mumbai
Date: 14th November 2026
UDIN:26030850VOXJXZ2620

UNIHEALTH HOSPITALS LIMITED
(Formerly known as UNIHEALTH CONSULTANCY LIMITED)
H-13/14 Everest, 156, Tardeo Road, Mumbai, Maharashtra 400034
CIN : L85100MH2010PLC200491

UNAUDITED STANDALONE STATEMENT OF FINANCIAL RESULTS FOR THE HALF YEAR ENDED 30TH SEPTEMBER 2026

(Rs. In lakhs)

	PARTICULARS	HALF YEAR ENDED			YEAR ENDED
		30.09.2026	31.03.2026	30.09.2025	31.03.2026
		Unaudited	Audited	Unaudited	Audited
		Refer note 1	Refer note 1	Refer note 1	Refer note 1
1	**Revenue from operations**	155.13	367.06	286.90	653.96
2	**Other income**	296.39	402.94	265.95	668.89
3	**Total revenue**	**451.52**	**770.00**	**552.85**	**1,322.85**
4	**Expenses**				
	Purchases of stock in trade	-	75.66	-	75.66
	Changes in inventories of Finished goods, Work in progress and Stock-in- trade	-	-	-	-
	Employee benefits expense	100.29	89.70	87.02	176.72
	Finance costs	2.97	2.17	8.27	10.44
	Depreciation and amortization expense	10.55	11.38	12.43	23.81
	Other expenses	62.06	72.92	80.29	153.21
5	**Total Expense**	**175.87**	**251.83**	**188.01**	**439.84**
6	**Profit/(Loss) before exceptional and Tax**	**275.65**	**518.17**	**364.84**	**883.01**
7	Exceptional Items	-	-	-	-
8	**Profit/(Loss) Before Tax**	**275.65**	**518.17**	**364.84**	**883.01**
9	**Tax expense**				
	(1) Current tax	69.62	139.91	92.93	232.84
	(2) Short/(Excess) provision of earlier year	-	0.16	-	0.16
	(3) Deferred tax	1.32	1.44	(0.56)	0.88
10	**Total Tax Expense**	**70.94**	**141.51**	**92.37**	**233.88**
11	**Profit After Tax for the period**	**204.71**	**376.66**	**272.47**	**649.13**
12	**Share in profit/(loss) of associates**	-	-	-	-
13	**Profit for the period**	**204.71**	**376.66**	**272.47**	**649.13**
14	**Other Comprehensive Income / (Expense)**				
	(A) Items that will not be reclassified to profit or loss				
	a) Remeasurement Gain/(Loss) on defined benefit plans	**1.49**	**11.68**	**(2.22)**	**9.46**
	b) Income Tax relating to items that will not be reclassified to Profit and Loss	**(0.37)**	**(2.94)**	**0.56**	**(2.38)**
	(B) Items that will be reclassified to profit or loss				
	a) Exchange difference in translating financials of foreign operations	-	-	-	-
	b) Income Tax relating to items that will not be reclassified to Profit and Loss	-	-	-	-
	Total Other Comprehensive Income / (Expense), Net of Tax	**1.12**	**8.74**	**(1.66)**	**7.08**
15	**Total Comprehensive Income for the period**	**205.83**	**385.40**	**270.81**	**656.21**
16	**Details of Equity Share Capital**				
	Paid-up Equity Share Capital	**1,715.00**	**1,570.00**	**1,550.00**	**1,570.00**
	Face Value of equity share capital	**Rs 10/-**	**Rs 10/-**	**Rs 10/-**	**Rs 10/-**
	Reserves excluding revaluation reserve				**6,362.31**
17	**Earnings per equity share:**				
	(a) Basic EPS from continuing and discontinued operations	**1.27**	**2.49**	**1.77**	**4.19**
	(b) Diluted EPS from continuing and discontinued operations	**1.26**	**2.46**	**1.77**	**4.15**

NOTES :

1 The standalone/Consolidated unaudited financial results has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting standard (Ind As) 34 - "Interim Financial Reporting" as prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and in terms of Regulation 33 of SEBI (Listing Obligation and Disclosure

2 The standalone unaudited financial results ("the Statement") of the Company for the Half year ended on September 30, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on 14 November, 2026 .The statutory auditor has expressed an unmodified review conclusion on the standalone unaudited financial results for the Half year ended on September 30, 2026, as required by regulation 33 of SEBI (LODR) regulations, 2015.

3 Basic earnings per share are calculated by dividing the profit after Tax for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the period. The net profit for the period attributable to equity shareholders and the weighted average number of shares outstanding during the period are adjusted for the effects of 2 lakh number of equity share warrants amouting to Rs.302 lakhs outstanding at the end of 30 September 2026 for computing dilutive potential equity shares.

4 The Figures for half year ended 31 st March 2026 are the balancing figures between the audited figures in respect of Financial year 2025-26 and the Published unaudited figures of Half year ended september 30, 2025 , which were subject to limited review.

5 During the period, the Company acquired an additional 49.81% equity stake in Victoria Hospitals Limited (VHL) for an aggregate consideration of ₹6,504 lakhs. Prior to this acquisition, the Company already held 50% equity stake in VHL. Consequently, upon completion of the acquisition, the Company's total shareholding in VHL increased to 99.81%. This stake was acquired through the issuance of 12,50,000 fully paid up equity shares of the Company to the existing shareholders of VHL at an issue price of Rs. 520.31 per equity share as approved in its

6 The Company has alloted 7 Lakhs convertible warrants on 2nd May 2025 as approved by Shareholders at the Extra Ordinary General Meeting held on 9th April 2025. The Company has already converted 5 lakhs warrants into equity shares upto the date of results. The balance 2 lakhs warrants are outstanding and the company has received the full consideration against such warrants post the date of financial results. Accordingly, The balance 2 lakhs warrants converted into equal number of equity share subsequent to the date of financial results.

7 The aforesaid results have been filed with Stock Exchanges under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are also available on the Stock Exchanges websites and on the website of the Company.

8 The Company is not a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P /2018/144 dated 26th November, 2018.

9 There are no investors complaints pending as on 30 September, 2026.

10 Segment information is presented in the "Consolidated Financial Results" as permitted under the Ind AS 108 -'Operating Segments'.

11 Figures for the previous periods /year have been regrouped ,restated and /or reclassified wherever considered necessary to make them comparable to the current periods /presentation.

12 The proceeds from the Equity shares IPO issued during FY 23-24 was amounting to Rs 5654.88 lakhs. The object and proposed utilization of IPO Proceeds and amount utilized as on September 30, 2026 is as under:-

Object	Amount Utilized
Investment in our joint venture, Victoria Hospital Limited (VHL), Kampala, Uganda for funding its capital expenditure requirements for proposed expansion and working capital requirements of VHL	1700.00
Investment in our joint venture, UMC Global Health Limited (UMCGHL), Nigeria for funding its capital expenditure requirements for proposed expansion	290.30
Investment in our subsidiary, Biohealth Limited (BL), Tanzania for funding its capital expenditure requirements for proposed e	237.50
Investment in our subsidiaries UMC Hospitals Private Limited (India) and in Unihealth Holdings Limited (Mauritius) to support expansion and acquisition of projects across India and Africa*	1350.00
General Corporate Purpose	1093.08
Issue Expenses	814.30

* The original object as disclosed in the offer document was further altered by passing a resolution to vary the utilisation of proceeds raised by the Company through an initial public offering of equity shares (the 'IPO') made in pursuance of the Prospectus dated September 14, 2023 (the 'Prospectus') and reallocate the unutilized proceeds for the objects as set out in the Postal Ballot Notice, have been passed with requisite majority on Wednesday, June 26, 2024. Out of initial proposed amount i.e. Rs. 1587.50 Lakhs, Rs.1350 Lakhs were reallocated for investing as equity and debt in UMC Hospitals Private Limited, a subsidiary of the Company in India and in Unihealth Holdings Limited, the wholly owned subsidiary of the Company in Mauritius, to support expansion and acquisition of projects across India and Africa, in furtherance of the current

For and on behalf of Board of
Unihealth Hospitals Limited
(Formerly known as Unihealth Consultancy Limited)

Akshay M Parmar
Managing Director
DIN:01533004
Place : Mumbai
Date: 14th November 2026

UNIHEALTH HOSPITALS LIMITED MUMBAI

UNIHEALTH HOSPITALS LIMITED

(Formerly known as Unihealth Consultancy Limited)

H-13/14 Everest, 156, Tardeo Road, Mumbai, Maharashtra 400034

CIN : L85100MH2010PLC200491

UNAUDITED STANDALONE STATEMENT OF ASSETS AND LIABILITIES AS AT 30TH SEPTEMBER 2026

(₹ in Lakhs)

Sr. No	Particulars	As at 30-Sep-2026 Unaudited Refer note 1	As at 31-Mar-2026 Audited Refer note 1
A.	**ASSETS**		
I	**Non-Current Assets**		
(a)	Property Plant and Equipment	277.99	287.35
(b)	Capital Work in Progress	-	-
(c)	Intangible Assets	2.09	2.52
(d)	Investment Property	-	-
(e)	Goodwill	-	-
(f)	Right-of-Use Assets	-	-
(g)	Financial Assets		
	(i) Investments	9,553.25	3,049.40
	(ii) Loans	4,478.40	3,693.26
	(iii) Others	97.95	5.47
(h)	Deferred Tax Assets	-	-
(i)	Other Non-current asstes	-	-
	Total Non-Current Assets	**14,409.68**	**7,038.00**
II	**Current Assets**		
(a)	Inventories	-	-
(b)	Financial Assets		
	(i) Investments	14.90	-
	(ii) Trade Receivables	233.70	456.33
	(iii) Cash and Cash Equivalents	230.44	309.98
	(iv) Bank Balance other than (iii) above	-	-
	(v) Loans	-	-
	(vi) Others	246.78	241.88
(c)	Current Tax Assets	-	-
(d)	Other Current Assets	153.51	130.79
(e)	Assets held for sale	-	-
	Total Current Assets	**879.33**	**1,138.98**
	Total Assets	**15,289.01**	**8,176.98**
B	**EQUITY AND LIABILITIES**		
I	**Equity**		
(a)	Equity Share Capital	1,715.00	1,570.00
(b)	Other Equity	13,153.50	6,362.31
	Total Equity	**14,868.50**	**7,932.31**
II	**Non-Current Liabilities**		
(a)	Financial Liabilities		
	(i) Borrowings	-	-
	(ii) Lease Liabilities	-	-
(b)	Provisions	31.03	24.17
(c)	Deferred Tax Liabilities	9.66	7.97
(d)	Others	97.83	-
	Total Non-Current Liabilities	**138.52**	**32.14**
III	**Current Liabilities**		
(a)	Financial Liabilities		
	(i) Borrowings	-	-
	(ii) Lease Liabilities	-	-
	(iii) Trade Payables		
	- Total Outstanding Dues of Micro Enterprises and Small Enterprises	18.60	19.76
	- Total Outstanding Dues of Creditors Other than Micro Enterprises and Small Enterprises	5.05	5.51
	(iv) Other Current Financial Liabilities	61.61	42.15
(b)	Other Current Liabilities	4.93	4.62
(c)	Provisions	191.80	140.49
	Total Current Liabilities	**281.99**	**212.53**
	Total Liabilities	**420.51**	**244.67**
	Total Equity and Liabilities	**15,289.01**	**8,176.98**

For and on behalf of Board of Unihealth Hospitals Limited
(Formerly known as Unihealth Consultancy Limited)

Akshay M Parmar
Managing Director
DIN:01533004
Place : Mumbai
Date: 14th November 2026

UNIHEALTH HOSPITALS LIMITED MUMBAI

UNIHEALTH HOSPITALS LIMITED
(Formerly known as Unihealth Consultancy Limited)
H-13/14 Everest, 156, Tardeo Road, Mumbai, Maharashtra 400034
CIN : L85100MH2010PLC200491

UNAUDITED STANDALONE CASH FLOW STATEMENT FOR THE HALF YEAR ENDED ON 30TH SEPTEMBER 2026

(₹ in Lakhs)

	Particulars	For the Half Year ended Unaudited	For the Year ended 31st March 2026 Audited
A	**Cash flow from operating activities**		
	Net profit before tax	275.65	883.01
	Adjustments for:		
	Depreciation/amortization	10.55	23.81
	Finance Cost	2.97	10.44
	Foreign exchange (gain)/Loss	(29.15)	(103.70)
	Gain on Sale of Invesment	(2.49)	-
	Gain on Change of Fair Value of Investments (measured at FVTPL)	(5.18)	-
	Interest on FD	-	(5.31)
	Interest on Loan given	(235.07)	(152.48)
	Operating profit before working capital changes	**17.28**	**655.77**
	Changes in assets and liabilities:		
	Increase / (decrease) in Trade Payables	(1.61)	12.35
	Increase / (Decrease) in Other Current Liabilities	0.31	(0.07)
	Increase / (decrease) in Provisions	59.67	122.14
	Increase / (decrease) in Other Financial Liabilities	117.28	15.56
	(Increase) / decrease in Other Financial Assets and Other Current Assets	(120.10)	(4.22)
	(Increase) / Decrease in Trade Receivables	222.63	(165.61)
	(Increase)/Decrease in Current Tax assets	-	-
	Cash (used in)/ generated from operating activities	**295.46**	**635.92**
	Income tax paid	(69.62)	(233.00)
	Net cash from/ (used in) from operating activities (A)	**225.84**	**402.92**
B	**Cash flow from Investing activities**		
	Proceeds/(investments) in fixed deposits & shares (net)	(6,511.09)	0.33
	Purchase of property, plant and equipment	(0.77)	0.94
	Loans (advanced)/received to/from Subsidiaries & Associates	(785.15)	(1,100.10)
	Interest received	-	5.31
	Interest on loan given	235.07	152.48
	Maturity proceeds of fixed deposits	-	400.00
	Net cash from/ (used in) from investing activities (B)	**(7,061.94)**	**(541.04)**
C	**Cash flow from Financing activities**		
	Proceeds from Issuance of Share Capital	6,730.36	453.00
	Proceeds from issue of Share warrants	-	151.00
	Proceeds/ (Repayment) of Borrowings	-	(265.50)
	Foreign exchange (gain)/Loss	29.15	103.70
	Finance cost	(2.97)	(10.44)
	Net cash from / (used in) from financing activities (C)	**6,756.54**	**431.76**
	Net increase / (decrease) in cash and cash equivalents (A+B+C)	(79.54)	293.64
	Cash and cash equivalents at the beginning of the year	309.98	16.34
	Cash and cash equivalents at the end of the year	**230.44**	**309.98**

For and on behalf of Board of Unihealth Hospitals Limited
(Formerly known as Unihealth Consultancy Limited)

Akshay M Parmar
Managing Director
DIN:01533004
Place : Mumbai
Date: 14th November 2026

UNIHEALTH HOSPITALS LIMITED MUMBAI

G. P. KAPADIA & CO.
Chartered Accountants
4th Floor, Hamam House, Ambalal Doshi Marg, Fort, Mumbai - 400 001
+ 91 22 2265 4239 / 4313 info.ho@gpkapadia.com www.gpkapadia.com

Independent Auditors' Review Report on the Unaudited Consolidated Financial Results of Unihealth Hospitals Limited (Formerly Known as Unihealth Consultancy Limited) for the half year ended 30th September, 2026 pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, as amended.

To,
The Board of Directors Unihealth Hospitals Limited
(Formerly Known as Unihealth Consultancy Limited)

1. We have reviewed the accompanying statement of consolidated unaudited financial results of **Unihealth Hospitals Limited** (the "Holding Company')*(Formerly Known as Unihealth Consultancy Limited)* and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") and its associates for the half year ended September 30, 2026 ("the Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (the 'Listing Regulation'). The Statement is the responsibility of the Holding Company's management and has been approved by the board of Directors. Our responsibility is to issue a report on the Statement based on our review.

2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013,as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulation. Our responsibility is to express a conclusion on the Statement based on our review

3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review consists of interim financial information consists of making inquiries, primarily of Holding Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:

Name of the Entity	Relationship
Aryavarta FZE	Wholly owned Subsidiary
Unihealth Pharmaceuticals Private Limited	Wholly owned Subsidiary
Unihealth Holdings Limited	Wholly owned Subsidiary
UMC Hospitals Private Limited	Subsidiary
Biohealth Limited	Subsidiary
Unihealth Tanzania Limited	Subsidiary
UMC Global Health Limited	Subsidiary
Victoria Hospitals Limited	Subsidiary
Unihealth (U) Limited	Associate

5. Emphasis of Matter

Attention is drawn to Note no. 10 regarding revision in the accounting estimates (revision in method of charging depreciation from Written Down Value to Straight Line Method for the Building (ROU class of asset) of one of the subsidiary namely UMC Hospitals Private Limited, based on the Management estimates. The management believes that charging depreciation on straight line method reflects appropriate disclosure of building ROU's net/ residual value.

As a result of the above,

(i) The depreciation charge for the half year ended 30th September 2026 is lower by 28.92 Lakhs.

(ii) Profit before Tax is higher by Rs. 28.92 Lakhs, deferred tax income is lower by Rs. 14.60 Lakhs and Profit after tax is higher by Rs. 14.32 for the half year ended 30th September 2026

(iii) Other equity is higher by Rs. 14.32 Lakhs, Deferred Tax asset is lower by Rs. 14.60 lakhs and net value of property, plant and equipment is higher by Rs. 28.92 Lakhs for the half year ended 30th September 2026.

Our conclusion on the Statement is not modified in respect of the above matters.

6. The Statement includes the results of the following entities.

(i) Two subsidiaries, whose results reflect total assets of Rs.27,439.02 lakhs as at 30th September 2026, total revenues of Rs.7,258.66 lakhs and net cash inflow of Rs 227.42 lakhs for the half year period ended on that date, as considered in the unaudited consolidated financial results, out of which one subsidiary whose result reflect total assets of Rs 16,800.88 lakhs as at 30th September 2026, total revenues of Rs.6,388.05 lakhs and net cash inflow of Rs 245.53 lakhs for the half year period ended on that date, have been reviewed by other independent auditors and our conclusion on the unaudited consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of that subsidiary company is based solely on the financial result of subsidiary referred aforesaid.

(ii) We did not review the interim financial results of Six Subsidiaries included in the consolidated unaudited financial results, whose interim financial results reflect unaudited total assets of Rs.4,287.50 lakhs and cash flows of Rs.320.53 lakhs as at 30th September 2026, unaudited total revenue from operations of Rs. 356.06 lakhs for the period ended 30 September 2026 and Loss from One Associates of Rs.10.27 lakhs, as considered in the unaudited consolidated financial results. These financial results have been prepared by the management and provided to us duly certified and our conclusion on the unaudited consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of those Subsidiary companies and Associate is based solely on the financial result of the subsidiaries and associate as referred aforesaid.

Our conclusion on the Statement is not modified in respect of the above matters.

7. Based on our review conducted and procedures performed as stated in paragraph 2 above, nothing has come to our attention that causes us to believe that the Statement has been prepared in all material respects in accordance with applicable Indian Accounting Standards ('Ind AS') prescribed under section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014 and other recognized accounting practices and policies, and has disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 (as amended) including the manner in which it is to be disclosed, or that it contains any material misstatement.

For G.P Kapadia & Co.
(Chartered Accountants)
FRN No.: 104768W

Atul Babubhai Desai

Digitally signed by Atul Babubhai Desai
Date: 2026.11.14 18:16:58 +05'30'

Atul Desai
(Partner)
Membership No. 030850
Place: Mumbai
Date:14th November 2026
UDIN:26030850KZTIET8037

UNIHEALTH HOSPITALS LIMITED
(Formerly known as UNIHEALTH CONSULTANCY LIMITED)
H-13/14 Everest, 156, Tardeo Road, Mumbai, Maharashtra 400034
CIN : L85100MH2010PLC200491

UNAUDITED CONSOLIDATED STATEMENT OF FINANCIAL RESULTS FOR THE HALF YEAR ENDED 30TH SEPTEMBER 2026

(₹ in Lakhs)

	PARTICULARS	HALF YEAR ENDED			YEAR ENDED
		30.09.2026	31.03.2026	30.09.2025	31.03.2026
		Unaudited	Audited	Unaudited	Audited
1	**Revenue from operations**	7,644.45	6,532.21	6,666.62	13,198.83
2	**Other income**	133.36	212.60	289.80	502.40
3	**Total revenue**	**7,777.81**	**6,744.81**	**6,956.42**	**13,701.23**
4	**Expenses**				
	Cost of Materials consumed	232.93	100.19	-	100.19
	Purchases of stock in trade	1,262.25	1,429.57	1,246.88	2,676.45
	Changes in inventories of Finished goods, Work in progress and Stock-in- trade	75.57	(260.04)	73.50	(186.54)
	Employee benefits expense	1,211.97	1,037.36	787.15	1,824.51
	Finance costs	184.25	115.65	118.31	233.96
	Depreciation and amortization expense	572.28	633.79	384.64	1,018.43
	Other expenses	2,404.70	2,017.60	1,387.22	3,404.82
5	**Total Expense**	**5,943.95**	**5,074.12**	**3,997.70**	**9,071.82**
6	**Profit/(Loss) before exceptional and Tax**	**1,833.86**	**1,670.69**	**2,958.72**	**4,629.41**
7	Exceptional Items	-	-	-	-
8	**Profit/(Loss) Before Tax**	**1,833.86**	**1,670.69**	**2,958.72**	**4,629.41**
9	**Tax expense**				
	(1) Current tax	80.61	178.17	96.62	274.79
	(2) Deferred tax	(425.23)	(230.96)	27.81	(203.15)
	(3) Short/(Excess) provision of earlier year	15.85	12.95	-	12.95
10	**Total Tax Expense**	**(328.77)**	**(39.84)**	**124.43**	**84.59**
11	**Profit After Tax for the period**	**2,162.63**	**1,710.53**	**2,834.29**	**4,544.82**
12	**Share in profit/(loss) of associates**	**(10.27)**	**(1.12)**	**28.89**	**27.77**
13	**Profit for the period**	**2,152.36**	**1,709.41**	**2,863.18**	**4,572.59**
14	**Other Comprehensive Income / (Expense)**				
	(A) Items that will not be reclassified to profit or loss				
	a) Remeasurement Gain/(Loss) on defined benefit plans	**5.46**	**11.68**	**(2.22)**	**9.46**
	b) Income Tax relating to items that will not be reclassified to Profit and Loss	**(1.37)**	**(2.94)**	**0.56**	**(2.38)**
	(B) Items that will be reclassified to profit or loss				
	a) Exchange difference in translating financials of foreign operations	-	-	-	-
	b) Income Tax relating to items that will not be reclassified to Profit and Loss	-	-	-	-
	Total Other Comprehensive Income / (Expense), Net of Tax	**4.09**	**8.74**	**(1.66)**	**7.08**
15	**Net Profit/(Loss) for the period attributable to:**	**2,152.36**	**1,709.41**	**2,863.18**	**4,572.59**
	Owners of the Company	**1,422.16**	**1,072.20**	**1,510.83**	**2,583.03**
	Non Controlling Interest	**730.20**	**637.21**	**1,352.35**	**1,989.56**
16	**Other Comprehensive Income/(Expense) attributable to:**	**4.09**	**8.74**	**(1.66)**	**7.08**
	Owners of the Company	**3.49**	**8.74**	**(1.66)**	**7.08**
	Non Controlling Interest	**0.60**	-	-	-
17	**Total comprehensive income attributable to:**	**2,156.45**	**1,718.15**	**2,861.52**	**4,579.67**
	Owners of the Company	**1,425.64**	**1,080.94**	**1,509.17**	**2,590.11**
	Non Controlling Interest	**730.81**	**637.21**	**1,352.35**	**1,989.56**
18	**Details of Equity Share Capital**				
	Paid-up Equity Share Capital	**1,715.00**	**1,570.00**	**1,550.00**	**1,570.00**
	Face Value of equity share capital	**Rs 10/-**	**Rs 10/-**	**Rs 10/-**	**Rs 10/-**
	Reserves excluding revaluation reserve				**12,191.05**
19	**Earnings per equity share:**				
	(a) Basic EPS from continuing and discontinued operations	**8.86**	**6.92**	**9.80**	**16.67**
	(b) Diluted EPS from continuing and discontinued operations	**8.77**	**6.86**	**9.79**	**16.52**

NOTES :

1 The standalone/Consolidated financial results of the company have been prepared in, accordance with Indian Accounting standards (Ind AS) as prescribed under section 133 of the companies Act 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (LODR) Regulation, 2015. The company has also reclassified the previous figures in accordance with the requirements applicable in the current period.

2 The Consolidated unaudited financial results ("the Statement") of the Company for the Half year ended on September 30, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on 14 November, 2026 .The statutory auditor has expressed an unmodified review conclusion on the Consolidated unaudited financial results for the Half year ended on September 30, 2026, as required by regulation 33 of SEBI (LODR) regulations, 2015.

3 Basic earnings per share are calculated by dividing the profit after Tax for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the period. The net profit for the period attributable to equity shareholders and the weighted average number of shares outstanding during the period are adjusted for the effects of 2 lakh number of equity share warrants amouting to Rs.302 lakhs outstanding at the end 30 September 2026 for computing dilutive potential equity shares.

4 The figures for the half year ended 31st March 2026 are the balancing figures between the audited figures in respect of Financial Year 2025-26 and the Published unaudited figures of Half year ended 30 September 2025, which were subject to limited review.

5 The Company has alloted 7 Lakhs convertible warrants on 2nd May 2025 as approved by Shareholders at the Extra Ordinary General Meeting held on 9th April 2025. The Company has already converted 5 lakhs warrants into equity shares upto the date of results. The balance 2 lakhs warrants are outstanding and the company has received the full consideration against such warrants post the date of financial results. Accordingly, The balance 2 lakhs warrants converted into equal number of equity share subsequent to the date of financial results.

6 The aforesaid results have been filed with Stock Exchanges under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are also available on the Stock Exchanges websites and on the website of the Company.

7 The Company is not a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P /2018/144 dated 26th November, 2018.

8 There are no investors complaints pending as on 30 September, 2026.

9 Segment information is presented in the "Consolidated Financial Results" as permitted under the Ind AS 108 -'Operating Segments'.

10 During the period, one of the subsidiaries namely "UMC Hospitals Private Limited" has carried out revision in the accounting esitmate (Method of Charging Depreciation from Written Down Value to Straight Line Method) for the Buidling (ROU Class of Assets), based on management's estimates. The management believes that charging depreciation basis Straight Line Method reflects the appropriate disclosure of Building ROU's net/residual value. As a result, (i) The depreciation charge for the half year ended 30th September 2036 is lower by 28.92 Lakhs. (ii) Profit before Tax is higher by Rs. 28.92 Lakhs, deferred tax income is lower by Rs. 14.60 lakhs and Profit after tax is higher by Rs. 14.32 lakhs for the half year ended 30th September 2026 and; (iii Other equity is higher by Rs. 14.32 Lakhs, Deferred Tax asset is lower by Rs. 14.60 lakhs and net value of property, plant and equipment is higher by Rs. 28.92 Lakhs for the half year ended 30th September 2026.

11 The proceeds from the Equity shares IPO issued during FY 23-24 was amounting to Rs 5654.88 lakhs. The object and proposed utilization of IPO Proceeds and amount utilized as on September 30, 2026 is as under:-

Object	Amount
Investment in our joint venture, Victoria Hospital Limited (VHL), Kampala, Uganda for funding its capital expenditure requirements	1700.00
Investment in our joint venture, UMC Global Health Limited (UMCGHL), Nigeria for funding its capital expenditure requirements for	290.30
Investment in our subsidiary, Biohealth Limited (BL), Tanzania for funding its capital expenditure requirements for proposed	237.50
Investment in our subsidiaries UMC Hospitals Private Limited (India) and in Unihealth Holdings Limited (Mauritius) to support	1350.00
General Corporate Purpose	1093.08
Issue Expenses	814.30

* The original object as disclosed in the offer document was further altered by passing a resolution to vary the utilisation of proceeds raised by the Company through an initial public offering of equity shares (the 'IPO') made in pursuance of the Prospectus dated September 14, 2023 (the 'Prospectus') and reallocate the unutilized proceeds for the objects as set out in the Postal Ballot Notice, have been passed with requisite majority on Wednesday, June 26, 2024. Out of initial proposed amount i.e. Rs. 1587.50 Lakhs, Rs.1350 Lakhs were reallocated for investing as equity and debt in UMC Hospitals Private Limited, a subsidiary of the Company in India and in Unihealth Holdings Limited, the wholly owned subsidiary of the Company in Mauritius, to support expansion and acquisition of projects across India and Africa, in furtherance of the current objects of the Company.

12 Figures for the previous periods /year have been regrouped ,restated and /or reclassified wherever considered necessary to make them comparable to the current periods /presentation.

For and on behalf of Board of
Unihealth Hospitals Limited
(Formerly known as Unihealth Consultancy Limited)

Akshay M Parmar
Managing Director
DIN:01533004
Place : Mumbai
Date: 14th November 2026

UNIHEALTH HOSPITALS LIMITED MUMBAI

UNIHEALTH HOSPITALS LIMITED
(Formerly known as UNIHEALTH CONSULTANCY LIMITED)
H-13/14 Everest, 156, Tardeo Road, Mumbai, Maharashtra 400034
CIN : L85100MH2010PLC200491

UNAUDITED CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES AS AT 30 SEPTEMBER 2026

(₹ in Lakhs)

Sr. No.	Particulars	As at 30-09-2026 (Unaudited)	As at 31-03-2026 (Audited)
A.	**ASSETS**		
I	**Non-Current Assets**		
(a)	Property Plant and Equipment	9,202.15	6,494.26
(b)	Capital Work in Progress	112.26	960.86
(c)	Intangible Assets	8.09	8.53
(d)	Investment Property	-	-
(e)	Goodwill	891.42	891.42
(f)	Right-of-Use Assets	6,098.32	1,042.35
(g)	Financial Assets		
	(i) Investments	36.00	46.26
	(ii) Loans	-	-
	(iii) Others	241.64	196.50
(h)	Deferred Tax Assets	248.02	-
(i)	Other Non-current asstes	352.29	188.87
	Total Non-Current Assets	**17,190.19**	**9,829.05**
II	**Current Assets**		
(a)	Inventories	647.43	684.49
(b)	Financial Assets		
	(i) Investments	14.90	-
	(ii) Trade Receivables	11,439.31	12,337.95
	(iii) Cash and Cash Equivalents	1,217.28	1,044.63
	(iv) Bank Balance other than (iii) above	-	-
	(v) Loans and Advances	-	-
	(vi) Others	673.07	110.22
(c)	Contract Assets	10.51	4.99
(d)	Other Current Assets	1,452.87	1,404.69
(e)	Assets held for sale	-	-
	Total Current Assets	**15,455.37**	**15,586.97**
	Total Assets	**32,645.56**	**25,416.02**
B	**EQUITY AND LIABILITIES**		
I	**Equity**		
(a)	Equity Share Capital	1,715.00	1,570.00
(b)	Other Equity	13,161.71	12,191.05
(c)	Non Controlling Interest	6,765.56	6,034.76
	Total Equity	**21,642.27**	**19,795.81**
II	**Non-Current Liabilities**		
(a)	Financial Liabilities		
	(i) Borrowings	2,267.69	1,609.43
	(ii) Lease Liabilities	5,881.95	926.33
	(iii) Others	-	-
(b)	Provisions	45.66	31.22
(c)	Deferred Tax Liabilities	-	130.90
(d)	Others	-	-
	Total Non-Current Liabilities	**8,195.30**	**2,697.88**
III	**Current Liabilities**		
(a)	Financial Liabilities		
	(i) Borrowings	569.29	521.35
	(ii) Lease Liabilities	209.25	217.29
	(iii) Trade Payables		
	Total Outstanding Dues of Micro Enterprises and Small Enterprises	457.65	718.02
	Total Outstanding Dues of Creditors Other than Micro Enterprises and Small Enterprises	350.06	220.00
		-	-
	(iv) Other Current Financial Liabilities	98.61	253.23
(b)	Other Current Liabilities	395.68	375.98
(c)	Provisions	727.45	616.46
	Total Current Liabilities	**2,807.99**	**2,922.33**
	Total Liabilities	**11,003.29**	**5,620.21**
	Total Equity and Liabilities	**32,645.56**	**25,416.02**

For and on behalf of Board of
Unihealth Hospitals Limited
(Formerly known as Unihealth Consultancy Limited)

Akshay M Parmar
Managing Director
DIN:01533004
Place : Mumbai
Date: 14th November 2026

UNIHEALTH HOSPITALS LIMITED MUMBAI

UNIHEALTH HOSPITALS LIMITED

(Formerly known as UNIHEALTH CONSULTANCY LIMITED)

H-13/14 Everest, 156, Tardeo Road, Mumbai, Maharashtra 400034

CIN : L85100MH2010PLC200491

UNAUDITED CONSOLIDATED CASH FLOW STATEMENT FOR THE HALF YEAR ENDED ON 30 SEPTEMBER 2026

(₹ in Lakhs)

	Particulars	For the Period ended 30-Sept-2026 (Unaudited)	For the Year ended 31-Mar-2026 (Audited)
A.	**Cash flows from operating activities**		
	Profit/(loss) before tax	1,833.86	4,629.41
	Depreciation and amortisation expenses	572.28	1,018.43
	Interest Income	(49.32)	(29.18)
	Finance cost	184.25	233.96
	Unrealised foreign exchange (gain)/Loss	(31.85)	(430.81)
	Gain on Sale of Invesment	(2.49)	-
	Gain on Change of Fair Value of Investments (measured at FVTPL)	(5.18)	-
	Operating profit / (loss) before working capital changes	**2,501.55**	**5,421.81**
	Changes in working capital:		
	Increase / (decrease) in trade payables	(130.31)	344.35
	Increase / (Decrease) in other current liabilities	19.70	541.22
	Increase / (decrease) in provisions	130.90	65.89
	Increase / (decrease) in other current financial liabilities	(154.62)	(252.14)
	(Increase) / decrease in other financial assets and other current assets	(819.59)	(875.89)
	(Increase) / Decrease in trade receivables	898.64	(4,122.34)
	(Increase) / Decrease in contract assets	(5.52)	(4.99)
	(Increase) / decrease in inventories	37.06	(260.91)
	Net changes in working capital	**(23.74)**	**(4,564.81)**
	Cash flow from operating activities post working capital changes	**2,477.81**	**857.01**
	Less: Income taxes (paid)/refunded, net	(95.08)	(287.74)
	Net cash generated from / (used in) operating activities (A)	**2,382.73**	**569.26**
B.	**Cash flows from investing activities**		
	Proceeds/(investments) in fixed deposits & shares (net)	(7.22)	
	Purchase of property, plant and equipment	(7,487.22)	(3,122.48)
	Interest received	49.32	29.18
	(Increase)/Decrease in bank balances other than cash and cash equivalents	-	725.00
	Net cash generated from / (used in) investing activities (B)	**(7,445.12)**	**(2,368.30)**
C.	**Cash flows from financing activities**		
	Proceeds from non current borrowings	658.27	1,070.78
	Proceeds from current borrowings (net)	47.94	(577.30)
	Proceeds from issue of equity shares	(266.35)	453.00
	Proceeds from issue of money warrants	-	151.00
	Interest on lease liability	(83.48)	(82.09)
	Payment of lease liabilities	4,846.81	561.09
	Net cash generated from / (used in) financing activities (C)	**5,203.19**	**1,576.48**
	Net increase / (decrease) in cash and cash equivalents (A+B+C)	**140.80**	**(222.56)**
	Cash and Cash equivalents at the beginning of the year	1,044.63	836.38
	Effect of foreign exchange gain/loss	31.85	430.81
	Cash and Cash equivalents at end of year	**1,217.28**	**1,044.63**

For and on behalf of Board of

Unihealth Hospitals Limited

(Formerly known as Unihealth Consultancy Limited)

Akshay M Parmar
Managing Director
DIN:01533004
Place : Mumbai
Date: 14th November 2026

UNIHEALTH HOSPITALS LIMITED MUMBAI

UNIHEALTH HOSPITALS LIMITED
(Formerly known as UNIHEALTH CONSULTANCY LIMITED)
H-13/14 Everest, 156, Tardeo Road, Mumbai, Maharashtra 400034
CIN : L85100MH2010PLC200491

UNAUDITED CONSOLIDATED SEGMENT INFORMATION FOR THE HALF YEAR ENDED ON 30 SEPTEMBER 2026

(₹ in Lakhs)

	PARTICULARS	HALF YEAR ENDED			YEAR ENDED
		30.09.2026	31.03.2026	30.09.2025	31.03.2026
		Unaudited	Audited	Unaudited	Audited
1	**Segment Revenue**				
	India	1,550.06	1,596.12	898.86	2,494.98
	Uganda	6,427.09	5,202.57	6,324.31	11,526.88
	Tanzania*	47.67	(5.61)	25.40	19.79
	Nigeria	15.12	62.40	10.06	72.46
	Mauritius	131.99	11.70	14.41	26.11
	UAE	61.85	442.24	-	442.24
2	**Total Segment Revenue**	**8,233.78**	**7,309.42**	**7,273.04**	**14,582.46**
3	Less: Inter Segment Revenue	455.97	564.61	316.62	881.23
4	**Total Segment Revenue from Operations**	**7,777.81**	**6,744.81**	**6,956.42**	**13,701.23**
5	**Segment Results (Profit Before Tax)**				
	India	(733.07)	(282.49)	191.65	(90.84)
	Uganda	2,385.52	1,519.89	2,849.77	4,369.66
	Tanzania	(5.41)	(11.54)	(42.05)	(53.59)
	Nigeria	0.04	28.20	(47.90)	(19.70)
	Mauritius	130.38	(8.83)	11.46	2.63
	UAE	56.40	425.46	(4.21)	421.25
6	**Total Segment Results (Profit Before Tax)**	**1,833.86**	**1,670.69**	**2,958.72**	**4,629.41**
7	**Segment Assets**				
	India	26,755.88	12,766.50	10,488.54	12,766.50
	Uganda	16,809.08	16,328.79	15,410.19	16,328.79
	Tanzania	729.31	648.81	573.34	648.81
	Nigeria	727.19	750.61	622.90	750.61
	Mauritius	601.95	463.62	443.15	463.62
	UAE	1,340.17	1,266.82	757.02	1,266.82
8	**Total Segment Assets**	**46,963.58**	**32,225.15**	**28,295.14**	**32,225.15**
9	Less: Inter Segment Elimination	14,318.02	6,809.13	6,188.45	6,809.13
10	**Total Assets**	**32,645.56**	**25,416.02**	**22,106.69**	**25,416.02**
11	**Segment Liabilities**				
	India	12,526.32	4,710.25	2,417.34	4,710.25
	Uganda	2,760.93	4,252.19	4,656.06	4,252.19
	Tanzania	924.53	833.02	726.85	833.02
	Nigeria	367.85	391.31	345.21	391.31
	Mauritius	6.95	6.32	1.51	6.32
	UAE	10.47	21.08	5.50	21.08
12	**Total Segment Liabilities**	**16,597.05**	**10,214.17**	**8,152.47**	**10,214.17**
	Less: Inter Segment Elimination	5,593.76	4,593.96	3,978.23	4,593.96
13	**Total Liabilities**	**11,003.29**	**5,620.21**	**4,174.24**	**5,620.21**

** The revenue for the half year ending on 31 March 2026 is a balancing figure between the revenue for the full year ending on 31 March 2026 and half year ending on 30 September 2025. Due to depreciation in currency (TZS), the revenue in Tanzania for the Half year ending on 31 March 2026 has arrived in negative amounts.*

For and on behalf of Board of
Unihealth Hospitals Limited
(Formerly known as Unihealth Consultancy Limited)

Akshay M Parmar
Managing Director
DIN:01533004
Place : Mumbai
Date: 14th November 2026

UNIHEALTH HOSPITALS LIMITED MUMBAI

UniHealth

Date: November 14, 2026

To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd.,
Exchange Plaza,
Plot No. C-1, Block G,
Bandra Kurla Complex,
Bandra (E)
Mumbai – 400051

NSE SYMBOL: UNIHEALTH

Sub: Statement of Variation of proceeds of Initial Public Issue ("IPO") pursuant to Reg. 32 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations").

Dear Sir/ Madam,

Pursuant to Regulation 32 of SEBI Listing Regulations, as amended read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 November 11, 2024, we hereby inform that during the half year ended September 30, 2026, there is no deviation or variation of proceeds of utilisation of IPO. Hence, a statement confirming that there is no deviation or variation in the utilisation of these proceeds is enclosed herewith.

Further, please find enclosed the Certificate by the Statutory Auditor indicating utilisation of issue proceeds, pursuant to NSE circular No: NSE/CML/2024/23 dated September 05, 2024, duly approved by the Audit Committee at their meeting held on November 14, 2026 as **'Annexure B'**.

Kindly take it on your records.

Thanking you,

Yours faithfully,

For **Unihealth Hospitals Limited**
(Formerly known as Unihealth Consultancy Limited)

DESHNA JAIN
Digitally signed by DESHNA JAIN
Date: 2026.11.14 18:03:46 +05'30'

UNIHEALTH HOSPITALS LIMITED MUMBAI

Deshna Jain
Company Secretary & Compliance Officer

Encl: As above.

UniHealth

Annexure A

STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE

Statement on deviation / variation in utilisation of funds raised

Name of listed entity	Unihealth Hospitals Limited
Mode of Fund Raising	Public Issues of Equity shares
Date of Raising Funds	September 15, 2023
Amount Raised	Rs. 56,54,88,000/-
Report filed for half year ended	September 30, 2026
Monitoring Agency	Not Applicable
Monitoring Agency Name, if applicable	Not Applicable
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	No
If Yes, Date of shareholder Approval	NA
Explanation for the Deviation / Variation	NA
Comments of the Audit Committee after review	None
Comments of the auditors, if any	None

Objects for which funds have been raised and where there has been a deviation, in the following table

(Rs. In lakhs)

Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised	Amount of Deviation/ Variation for the half year ended 30.09.2026 according to applicable object	Remarks if any
Investment in our joint venture, Victoria Hospital Limited (VHL), Kampala, Uganda for funding its capital expenditure requirements for proposed expansion and working capital requirements of VHL	No Modification	1700.00	NA	1700.00	0	-
Investment in our joint venture, UMC Global Health Limited (UMCGHL), Nigeria for funding its capital expenditure requirements for proposed expansion	No Modification	460.00	NA	290.30	0	169.70 (Unutilized funds)
Investment in our subsidiary, Biohealth Limited (BL), Tanzania for funding its capital expenditure requirements for proposed expansion	As per the Prospectus, Rs. 1,587.50 lakhs was originally allocated to Biohealth Limited (BL), Tanzania for funding its capital expenditure. Out of this unutilized amount, Rs. 1,350 lakhs has now been reallocated to our subsidiaries, UMC Hospitals Private Limited (India) and Unihealth Holdings Limited (Mauritius) to support expansion and acquisition of projects across India and Africa	1587.50	237.50	237.50	0	-

NA	Investment in our subsidiaries namely UMC Hospitals Private Limited (India) and in Unihealth Holdings Limited (Mauritius) to support expansion and acquisition of projects across India and Africa	NIL	1350	1350	0	Shareholders approved the said reallocation of unutilized proceeds of Rs. 1,350 lakhs for the modified objects by passing special resolution through Postal Ballot on June 26, 2024 the said amount is allocated to them.
General Corporate Purpose	No Modification	1093.08	-	1093.08	0	-
Issue Expenses	No Modification	814.30	-	814.30	0	-

Deviation or variation could mean:
(a) Deviation in the objects or purposes for which the funds have been raised or
(b) Deviation in the amount of funds actually utilized as against what was originally disclosed or
(c) Change in terms of a contract referred to in the fund raising document i.e. prospectus, letter of offer, etc.

For **Unihealth Hospitals Limited**
(Formerly known as Unihealth Consultancy Limited)

DESHNA JAIN
Digitally signed by DESHNA JAIN
Date: 2026.11.14 18:04:06 +05'30'

Deshna Jain
Company Secretary & Compliance Officer

G. P. KAPADIA & CO.
Chartered Accountants
4th Floor, Hamam House, Ambalal Doshi Marg, Fort, Mumbai - 400 001
+ 91 22 2265 4239 / 4313 info.ho@gpkapadia.com www.gpkapadia.com

UTILIZATION OF ISSUE PROCEEDS CERTIFICATE

To,
Board of Directors,
Unihealth Hospitals Limited,
H-13/14 Everest, 156, Tardeo Road,
Mumbai, Maharashtra 400034

Respected Sir/Madam,

Sub: Certificate pursuant to NSE circular No, NSE/CML/2024/23 dated 5th September, 2024 for utilization of issue proceeds in relation to the initial Offer proceeds of public issue for Unihealth Hospitals Limited ("the Company").

We have been requested to certify the utilization of issue proceeds by the Company in relation to the Initial Offer proceeds of public issue of the Company. Based on verification of relevant documents and details furnished by the management of the company, we hereby certify, the utilization of Issue Proceeds of Initial Public offer of the company up to 30th September, 2026, as mentioned below in the prescribed

Annexure "A"

Sr No.	Object as disclosed in the Offer Document	Amount disclosed in the Offer Document	Actual Utilized Amount	Unutilized Amount	Remarks
1.	Investment in joint venture, Victoria Hospital Limited (VHL), Kampala, Uganda for funding its capital expenditure requirements for proposed expansion and working capital requirement of VHL	1700.00	1700.00	-	NIL
2.	Investment in Subsidiary, UMC Global Health Limited (UMCGHL), Nigeria for funding its capital expenditure requirements for proposed expansion. (Note 1)	460.00	290.30	169.70	NIL

3.	Investment in subsidiary, Biohealth Limited (BIO, Tanzania for funding its capital expenditure requirements for proposed expansion	237.50	237.50	-	NIL
4.	Investment in our subsidiaries UMC Hospitals Private Limited (India) and in Unihealth Holdings Limited (Mauritius) to support expansion and acquisition of projects across India and Africa	1350.00	1350.00	-	NIL
5.	General Corporate Purpose	1093.08	1093.08	-	NIL
6.	Issue Expenses (Net off from Gross IPO Proceeds of Rs.5654.88 Lakhs and Net IPO proceed As,4840.58 Lakhs as per offer document)	814.30	814.30	-	NIL
	Total	**5654.88**	**5476.32**	**169.70**	

Note 1: The company has maintained the required bank balance at the level of unutilized IPO proceeds in bank accounts of the company as on 30th September 2026.

Note 2 : The original object as disclosed in the offer document was further altered by passing a resolution to vary the utilization of proceeds raised by the Company through an initial public offering of equity shares (the 'IPO) made in pursuance of the Prospectus dated September 14, 2023 (the Prospectus') and reallocate the unutilized proceeds for the objects as set out in the Postal Ballot Notice, have been passed with requisite majority on Wednesday, June 26, 2024. Out of initial proposed amount i.e. Rs. 1587.50 Lakhs, Rs.1350 Lakhs were reallocated for investing as equity and debt in UMC Hospitals Private Limited, a subsidiary of the Company in India and in Unihealth Holdings Limited, the wholly owned subsidiary of the Company in Mauritius, to support expansion and acquisition of projects across India and Africa, in furtherance of the current objects of the Company. The utilized amount disclosed in the above table is consolidated utilized amount after considering the object reallocation as mentioned.

For G.P Kapadia & co
(Chartered Accountants)
FRN No.: 104768W

Atul Babubhai Desai
Digitally signed by Atul Babubhai Desai
Date: 2026.11.14 17:05:17 +05'30'

Atul Desai
(Partner)
Membership No. 030850
Place: Mumbai
Date: 14.11.2026
UDIN: 26030850FTXGFL6958

G. P. KAPADIA & CO.
Chartered Accountants
4th Floor, Hamam House, Ambalal Doshi Marg, Fort, Mumbai - 400 001
+ 91 22 2265 4239 / 4313 info.ho@gpkapadia.com www.gpkapadia.com

CERTIFICATE FOR UTILIZATION OF FUNDS

To,
Board of Directors,
Unihealth Hospitals Limited,
H-13/14 Everest, 156, Tardeo Road,
Mumbai, Maharashtra 400034

Subject: Certificate pursuant to NSE Circular No. NSE/CML/2024/23 dated September 05, 2024 for utilization of issue proceeds of Unihealth Hospitals Limited

Respected Sir/Madam,

We have been requested to certify the utilization of funds of the Company in relation to funds given to UMC Hospitals Private Limited. Based on verification of relevant documents and details furnished by the management of the company, we hereby certify, the utilization of funds given to UMC Hospitals Private Limited up to 30th September 2026, as mentioned below in the prescribed Annexure "A"

Annexure "A" (Rs. In Lakhs)

Object as disclosed in the Offer Document	Amt Received	Amt Utilized	Amt Unutilized
Investment as equity and debt in subsidiary, UMC Hospitals Pvt Ltd for funding its expansion and acquisition of projects	926.50 (Note 1)	926.50 (Note 2)	NIL

Note 1: The amount received from Unihealth Hospitals limited is inclusive of the following:

1. Rs.15,20,000 invested in the equity shares on 5th July 2024
2. Rs.7,44,80,000 invested in the equity shares through right issue on 9th December 2024
3. Rs 1,66,50,000 provided in the form of loan to the company during the year.

Note 2: The Amount Received from Unihealth Hospitals Limited Rs. 926.50 Lakhs is fully utilized for Expansion and Acquisition of Projects Till 30th September, 2026.

For G.P. Kapadia & Co.
(Chartered Accountants)
FRN No.: 104768W

Atul Babubhai Desai
Digitally signed by Atul Babubhai Desai
Date: 2026.11.14 17:08:30 +05'30'

Atul Desai
(Partner)
Membership No.030850
Place: Mumbai
Date: 14.11.2026
UDIN: 26030850BHVMMH7001

MHASIBU CONSULTANTS

Certified Public Accountants, Auditors & Tax Consultants
P. O. Box 13768, Jamhuri Street,
Benjamin W. Mkapa Parking Tower, Ground Floor, Dar es Salaam, Tanzania.
Tel: +255-22-2120248, 0735 991 002
E-mail: info@mhasibu.co.tz: Website: www.mhasibu.co.tz

TO WHOMSOEVER IT MAY CONCERN

On the basis of explanations given and evidences produced before us for our verification by BIOHEALTH LIMITED, incorporated in Tanzania under the companies act 2002 and that the company is limited, we certify that:

Biohealth Limited is a subsidiary of Unihealth Hospitals Limited (Formerly known as Unihealth Consultancy Limited) which got listed on the National Stock Exchange of India (NS E) in September 2023. One of the objectives of its Initial Public offering ('IPO') was to invest in its subsidiary, Biohealth Limited (BL), Tanzania for funding its capital expenditure requirements for proposed expansion.

As per amended IPO object of Unihealth Hospitals Limited the amount allocated to Biohealth Limited is Rs. 2,37,50,000 (Indian Rupees Two Crore Thirty-Seven Lacs Fifty Thousand Only) equivalent to USD 278,000.

Unihealth Hospitals Limited has extended fund of USD 200,000 (US Dollar Two Hundred Thousand) on 15th July 2024 and USD 78,000 (US Dollar Seventy-Eight Thousand) on 20th March 2025 to Biohealth Limited, Biohealth Limited has utilized this fund as below:

Sr. No.	Object as disclosed in Offer Document	Amount received till 30/09/2026	Actual utilized amount till 30/09/2026	Unutilized amount as on 30/09/2026
1.	Capital Expenditure for Expansion	USD 2,78,000	USD 2,78,000	USD NIL

On the basis of explanation given and documents produced before us for the verification, we Certify that above statement is true and correct.

MHASIBU CONSULTANTS

MHASIBU CONSULTANTS P.O. Box 13768, DSM PF No. 109 ACPA-PP 3817 TANZANIA

STANLEY TAGALILE (ACPA-PP)

For and on behalf of Mhasibu Consultants
Certified Public Accountants
Dar es Salaam

DATE: 29 OCTOBER, 2026

UHY
Connect to possibility

UHY & Co
UHY House,
71 Impasse Saipan,
Vivea Business Park,
Concordia, 81405, Moka,
MAURITIUS

T +230 460 9333
E contact@uhy.co.mu

uhy.co.mu

TO WHOMSOEVER IT MAY CONCERN

On the basis of explanations given and evidence produced before us for our verification by **Unihealth Holdings Limited**, a private company limited by shares, incorporated in Mauritius, situated at c/o NWT (Mauritius) Limited, 4th Floor Carleton Tower, Wall Street, Cybercity, Ebene 72201, Mauritius, we certify that:

Unihealth Holdings Limited is a subsidiary of Unihealth Hospitals Limited (formerly Unihealth Consultancy Limited) which got listed on the National Stock Exchange of India (NSE) in September 2023. One of the objectives of its Initial Public offering ('IPO') (amendment of which was approved by the shareholders through postal ballot notice dated 27 May 2024) was to invest in its subsidiary, Unihealth Holdings Limited for investing in operating companies in Tanzania and/or Nigeria and/or Ethiopia which may also extend to other countries and sectors as and when the opportunity arises. The targeted sector of investment will in the Medical and Healthcare field.

Unihealth Hospitals Limited has extended fund of USD 500,000 (US Dollar Five Hundred Thousand) to Unihealth Holdings Limited on 04 September 2024. Unihealth Holdings Limited has utilised this fund as below:

Sr. No.	Object as disclosed in Offer Document	Amount disclosed in the Offer Document	Actual utilised amount till 30/09/2026	Unutilised amount as on 30/09/2026
1	Investment in Medical and Healthcare fields	USD 500,000	USD 457,000	USD 43,000

On the basis of explanation given and documents produced before us for the verification, we certify that the above statement is true and correct.

UHY & Co

UHY & Co

Avinashsingh Mooruth, Licensed by FRC
Signing Partner

Date: 12 November 2026

Audit | Tax | Consulting

Urbach Hacker Young International Limited is the administrative entity of the international UHY network of independent accounting and consulting firms. The UHY network is a member of the Forum of Firms.

Urbach Hacker Young International Ltd. Registered office: Quadrant House, 4 Thomas More Square, London E1W 1YW. Registered in England 3692575

MEMBER OF THE FORUM OF FIRMS

Ibrahim Abdullahi & Co.
Chartered Accountants

Abuja Office:
Suite 414 Kings Plaza,
Plot 307, Cadastral Zone B09,
Kado District,
Abuja
Kano Office:
Suite 1, 3rd Floor Guda Abdullahi Road,
Farm Centre, Kano State
Tel: +234 80 3368 1014, +234 80 9939 0900

Lagos Office:
4 Dipeolu Street, Off Awolowo Way
Behind Tanterlizers Allen juntion,
Ikeja - Lagos State
Imo Office:
132 Wetheral Road, Owerri
Imo State

TO WHOMSOEVER IT MAY CONCERN

On the basis of explanations given and evidence produced before us for our verification by **UMC GLOBAL HEALTH LIMITED**, incorporated in Nigeria under the Companies and Allied Matters Act 1990 and that the company is limited, we certify that:

UMC Global Health Limited is a subsidiary (with effect from 1st October, 2024) of Unihealth Hospitals Limited (formerly known as Unihealth Consultancy Limited) which got listed on the National Stock Exchange of India (NSE) in September 2023. One of the objectives of its Initial Public offering ('IPO') was to invest in its subsidiary, UMC Global Health Limited, Nigeria for funding its capital expenditure requirements for proposed expansion.

UMC Global Health Limited is allocated an amount of Rs. 4,60,00,000 (Indian Rupees Four Crore Sixty Lacs Only) equivalent to USD 544,000 by Unihealth Hospitals Limited (Formerly known as Unihealth Consultancy Limited) and has extended fund of USD 50,000 on 01st February 2024, USD 50,000 on 21st March 2024, USD 33,740 on 23rd September 2024, USD 200,000 on 07th November 2024 and USD 10,000 on 03rd November 2025 to UMC Global Health Limited, UMC Global Health Limited has utilised this fund as below:

Sr. No.	Object as disclosed in Offer Document	Amount received till 30/09/2026	Actual utilized amount till 30/09/2026	Unutilized amount as on 30/09/2026
1.	Capital Expenditure for Expansion	USD 343,740	USD 343,740	USD NIL

On the basis of explanation given and documents produced before us for the verification, we certify that above statement is true and correct.

Abdulwaheed Ibrahim
FRC/2016/ICAN/00000014377
For: Ibrahim Abdullahi & Co.
(Chartered Accountants)

Date: 24th October 2026

Date: November 14, 2026

To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd.,
Exchange Plaza,
Plot No. C-1, Block G,
Bandra Kurla Complex,
Bandra (E) Mumbai – 400051

NSE SYMBOL: UNIHEALTH

Sub: Statement of deviation(s) / variation(s) in utilization of proceeds raised through Preferential Issue of the Company, pursuant to Regulation 32 of SEBI (LODR) Regulations, 2015 ("SEBI Listing Regulations) for the half year ended on September 30, 2026

Dear Sir/ Madam,

With reference to the above subject and pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, we hereby confirm that there has been no deviation or variation in the utilisation of proceeds raised through the preferential allotment of 7,00,000 Convertible Warrants issued at a price of Rs. 151/- each.

In accordance with the terms of the issue, the Company received 25% of the issue price per Convertible Warrant, i.e., Rs. 37.75 per Warrant, aggregating to Rs. 2,64,25,000/- at the time of allotment of the Warrants. Further, the Company has received Rs. 5,66,25,000/- upon conversion of 5,00,000 Convertible Warrants into an equal number of equity shares upto 30th September, 2026.

Accordingly, a statement confirming that there is no deviation or variation in the utilisation of these proceeds is enclosed herewith.

The Certificate issued by the Statutory Auditors in respect of utilisation of issue proceeds, in terms of NSE Circular No. NSE/CML/2024/23 dated September 05, 2024, is also enclosed below.

The aforesaid statement and certificate have been reviewed by the Audit Committee and taken on record by the Board of Directors at their respective meetings held on November 14, 2026. Kindly take it on your records.

Thanking you,

Yours faithfully,

UniHealth

For **Unihealth Hospitals Limited**
(Formerly known as Unihealth Consultancy Limited)

DESHNA JAIN

Digitally signed by DESHNA JAIN
Date: 2026.11.14 18:04:28 +05'30'

Deshna Jain
Company Secretary & Compliance Officer
Encl: As above.



Annexure A

STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PREFERENTIAL ISSUE

Statement on deviation / variation in utilisation of funds raised

Name of listed entity	Unihealth Hospitals Limited
Mode of Fund Raising	Preferential Issue of Convertible Equity Warrants
Date of Raising Funds	May 02, 2025
Amount Raised	Rs. 10,57,00,000/-
Report filed for half year ended	September 30, 2026
Monitoring Agency	Not Applicable
Monitoring Agency Name, if applicable	Not Applicable
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	No
If Yes, Date of shareholder Approval	None
Explanation for the Deviation / Variation	None
Comments of the Audit Committee after review	None
Comments of the auditors, if any	None

Objects for which funds have been raised and where there has been a deviation, in the following table

(Rs. In lakhs)

Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised	Amount of Deviation/ Variation for the half year ended 30.09.2026 according to applicable object	Remarks if any

Funding to its subsidiary, UMC Hospitals Private Limited to support capital expenditures (capex) and working capital requirements for the hospitals in India;	No Modification	845.60	NA	830.50	0	-
Working capital requirement of the Company, General Corporate Purpose, which includes, without limitation, strategic initiatives, funding growth opportunities, strengthening marketing capabilities and brand building exercises, meeting ongoing general corporate contingencies, fund raising expense and other expenses incurred in ordinary course of business	No Modification	211.40	NA	-	0	-

Deviation or variation could mean:
(a) Deviation in the objects or purposes for which the funds have been raised or
(b) Deviation in the amount of funds actually utilized as against what was originally disclosed or
(c) Change in terms of a contract referred to in the fund-raising document i.e. prospectus, letter of offer, etc.

For **Unihealth Hospitals Limited**
(Formerly known as Unihealth Consultancy Limited)

DESHNA JAIN Digitally signed by DESHNA JAIN
Date: 2026.11.14 18:04:41 +05'30'

Deshna Jain
Company Secretary & Compliance Officer

G. P. KAPADIA & CO.
Chartered Accountants
4th Floor, Hamam House, Ambalal Doshi Marg, Fort, Mumbai - 400 001
+ 91 22 2265 4239 / 4313 info.ho@gpkapadia.com www.gpkapadia.com

UTILIZATION OF FUNDS CERTIFICATE

To,
Board of Directors,
Unihealth Hospitals Limited,
H-13/14 Everest, 156, Tardeo Road,
Mumbai, Maharashtra 400034

Sub: Certificate Under Pursuant to NSE Circular No. NSE/CML/2024/23 dated September 05, 2024 for utilization of issue proceeds in relation to the proceeds of the issue from the Preferential Issue of Convertible Warrants ("Warrants") for Unihealth Hospitals Limited.

We have been requested to certify utilization of issue proceeds by the Company in relation to the proceeds of the issue from the Preferential Issue of Convertible Warrants ("Warrants"). For the purpose of certifying the below table, we have reviewed documents, statement, papers, books of accounts, and other relevant information of the Company on the proceeds of Preferential Issue of Convertible Warrants. Based on our review of the same, we hereby certify that up to September 30,2026, the Company has utilized the proceeds of Preferential Issue of Convertible Warrants for Unihealth Hospitals Limited as per the following details.

Objects for which funds have been raised and utilized is given in the following table.

Sr No.	Objects as disclosed in the Offer Document	Original Allocation (Rs. In Lakhs)	Preferential Issue Proceeds till 30.09.2026	Actual Utilized Amount till 30-09-2026 (Rs. in Lakhs)	Unutilized Amount as on 30-09-2026 (Rs. in Lakhs)	Remarks
1	Funding to its subsidiary, UMC Hospitals Private Limited to support capital expenditures (capex) and working capital requirements for the hospitals in India;	845.60 Lakhs (amount Received till 30th Sept 2026 – Rs.830.50	*Rs.830.50	Rs.830.50	NIL	NIL

2	Working capital requirement of the Company, General Corporate Purpose, which includes, without limitation, strategic initiatives, funding growth opportunities, strengthening marketing capabilities and brand building exercises, meeting ongoing general corporate contingencies, fund raising expense and other expenses incurred in ordinary course of business.	211.40		NIL	NIL	NIL
	Total	**1057.00**		**830.50**	**NIL**	

***Notes:**

The Company allotted 7,00,000 Warrants on May 02, 2025 on a preferential basis to the Promoters as approved by the shareholders at its Extra-Ordinary General Meeting held on April 09, 2025. Each warrant is issued at a price of Rs. 151/-.

1. The Company has received 25% of the issue price of the Warrants i.e. Rs. 37.75/- aggregating to a sum of Rs. 2,64,25,000/- on allotment of 7,00,000 Warrants in accordance with the specified terms of the issuance.

2. The Company has received the balance 75% of the issue price, amounting to Rs. 5,66,25,000/-, in respect of 5,00,000 Convertible Warrants, upon conversion of the said

G. P. KAPADIA & CO.
Chartered Accountants
4th Floor, Hamam House, Ambalal Doshi Marg, Fort, Mumbai - 400 001
+ 91 22 2265 4239 / 4313 info.ho@gpkapadia.com www.gpkapadia.com

warrants into equity shares and allotment of 5,00,000 equity shares, in accordance with the terms and conditions of the issue.

3. On September 08, 2025, January 12, 2026 and April 10, 2026 the Company allotted 1,00,000 (One Lakh), 2,00,000 (Two Lakhs) equity shares and 2,00,000 (Two Lakhs) equity shares respectively, having a face value of Rs.10/- each at a premium of Rs.141/- per share, pursuant to the conversion of an equivalent number of Convertible Warrants at an issue price of Rs.151/- per warrant, in accordance with the terms of the issue.

4. The Warrants are convertible into equal number of equity share and the conversion shall be exercised at any time during the period of 18 months from the date of allotment of the said Warrants on such other terms and conditions as applicable.

For G.P Kapadia & Co.
(Chartered Accountants)
FRN No.: 104768W

Atul Babubhai Desai
Digitally signed by Atul Babubhai Desai
Date: 2026.11.14 17:07:19 +05'30'

Atul B. Desai
(Partner)
Membership No: 030850
Place: Mumbai
Date: 14.11.2026
UDIN: 26030850DBXVIU1584

G. P. KAPADIA & CO.
Chartered Accountants
4th Floor, Hamam House, Ambalal Doshi Marg, Fort, Mumbai - 400 001
+ 91 22 2265 4239 / 4313 info.ho@gpkapadia.com www.gpkapadia.com

CERTIFICATE FOR UTILIZATION OF FUNDS

To,
Board of Directors,
Unihealth Hospitals Limited
H-13/14 Everest, 156, Tardeo Road,
Mumbai, Maharashtra 400034

Subject: Certificate pursuant to NSE Circular No. NSE/CML/2024/23 dated September 05, 2024 for utilization of funds received from Unihealth Hospitals Limited by UMC Hospitals Private Limited

Respected Sir/Madam,

We have been requested to certify the utilisation of proceeds received by **UMC Hospitals Private Limited** from Unihealth Hospitals Limited pursuant to the Preferential Issue of Convertible Warrants.

Based on our verification of the relevant books of account, records and supporting documents, and the information and explanations furnished by the Management of UMC Hospitals Private Limited, we hereby certify the utilisation of the aforesaid proceeds up to 30th September 2026, as detailed in the prescribed Annexure "A" attached herewith.

Annexure "A" (Rs. In Lakhs)

Object as disclosed in the Offer Document	Amt. Received	Amt. Utilized	Amt. Unutilized
Funding to its subsidiary, UMC Hospitals Private Limited to support capital expenditures (capex) and working capital requirements for the hospitals in India.	Rs.830.50 (Note 1)	Rs.830.50 (Note 2)	NIL

Note 1: The amount given to UMC Hospitals Private Limited out of Preferential Issue of Convertible Warrants issued by Unihealth Hospitals limited.

Note 2: The Amount given to UMC Hospitals Private Limited Rs.830.50 lakhs are Utilized for Capital Expenditure/Working Capital Requirement of the Company till 30th September 2026.

For G.P. Kapadia & Co.
(Chartered Accountants)
FRN No.: 104768W
Atul Babubhai Desai
Digitally signed by Atul Babubhai Desai
Date: 2026.11.14 17:09:21 +05'30'
Atul Desai
(Partner)
Membership No.030850
Place: Mumbai
Date: 14.11.2026
UDIN: 26030850ZDTZN93251